Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Why does neurodegeneration occur in Langerhans cell histiocytosis?
Discovering what causes nerve cells to stop working and die years after a Langerhans cell histiocytosis diagnosis.
Identifying a new blood cancer to improve the outlook for leukaemia patients
Looking at a new subtype of leukaemia, called CML-like Ph+ALL, to see how best to diagnose and treat it.
What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Understanding why some childhood blood cancers are incurable
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.
How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
A living review of new treatments for children and young people with relapsed and refractory rhabdomyosarcoma
Developing a living systematic review of studies into new treatments for relapsed and refractory rhabdomyosarcoma.